1. Short title This Act may be cited as the Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019 or the ACCESS for Biosimilars Act of 2019 . 2. Eliminating cost sharing for biosimilar biological products furnished under part B of the Medicare program Section 1833 of the Social Security Act ( 42 U.S.C. 1395l ) is amended— (1) in subsection (a)(1)(S), by inserting (or, in the case of such a biological that is a specified biosimilar biological product (as defined in subsection (cc)) furnished during a year (beginning with 2020) to an individual who is a cost-sharing reduction eligible individual (as defined in such subsection) with respect to such year, 100 percent) after 80 percent ; and (2) by adding at the end the following new subsection: (cc) Specified biosimilar biological product reduced cost-Sharing provisions (1) Definitions (A) Cost-sharing reduction eligible individual defined For purposes of subsection (a)(1)(S) and with respect to a year, the term cost-sharing reduction eligible individual means an individual who, as of January 1 of such year— (i) is enrolled under this part; and (ii) does not have qualifying coverage (as defined in subparagraph (B)). (B) Qualifying coverage (i) In general For purposes of subparagraph (A), the term qualifying coverage means, with respect to an individual, coverage— (I) under— (aa) a group health plan or health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act); (bb) a Federal health care program (as defined in section 1128B(f)), other than the program established under this title; (cc) the health insurance program under chapter 89 of title 5, United States Code; (dd) a medicare supplemental policy under section 1882; or (ee) an MA or MA–PD plan; and (II) that meets— (aa) in the case of coverage described in any of items (aa) through (dd) of subclause (I), the condition described in clause (ii)